{"id":1309,"date":"2014-11-28T20:11:00","date_gmt":"2014-11-28T20:11:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/on-jsc-grindeks-financial-results-for-nine-months-of-2014\/"},"modified":"2022-06-29T20:13:40","modified_gmt":"2022-06-29T20:13:40","slug":"on-jsc-grindeks-financial-results-for-nine-months-of-2014","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/on-jsc-grindeks-financial-results-for-nine-months-of-2014\/","title":{"rendered":"Par Grindeks finan\u0161u rezult\u0101tiem 2014. gada devi\u0146os m\u0113ne\u0161os"},"content":{"rendered":"\n<p>Piektdien, 28. novembr\u012b akciju sabiedr\u012bbas Grindeks \u201eNASDAQ OMX Riga\u201d iesniegtie 2014. gada devi\u0146u m\u0113ne\u0161u nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums 2014. gada devi\u0146os m\u0113ne\u0161os bija 63,1 milj. euro, kas ir par 17,3 milj. euro vai par 21,5% maz\u0101k nek\u0101 2013. gada devi\u0146os m\u0113ne\u0161os. Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2014. gada devi\u0146os m\u0113ne\u0161os bija 3,7 milj. euro, kas, sal\u012bdzinot ar 2013. gada devi\u0146iem m\u0113ne\u0161iem, ir samazin\u0101jusies par 4 milj. euro vai 52,4%.<\/p>\n\n\n\n<p>Bruto pe\u013c\u0146as rentabilit\u0101te 2014. gada devi\u0146os m\u0113ne\u0161os bija 58,3%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija 5,8%. 2014. gada devi\u0146os m\u0113ne\u0161os Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 57 pasaules valst\u012bm, kopum\u0101 par 59,7 milj. euro, kas ir par 16,4 milj. euro vai par 21,5% maz\u0101k nek\u0101 2013. gada devi\u0146os m\u0113ne\u0161os.<\/p>\n\n\n\n<ol class=\"wp-block-list\" start=\"2014\"><li>gada devi\u0146os m\u0113ne\u0161os apgroz\u012bjuma r\u0101d\u012bt\u0101ju, sal\u012bdzin\u0101jum\u0101 ar iepriek\u0161\u0113j\u0101 gada to pa\u0161u periodu, ir ietekm\u0113ju\u0161i vair\u0101ki b\u016btiski faktori \u2013 \u0123eopolitisk\u0101 situ\u0101cija Krievij\u0101 un Ukrain\u0101, kas veicin\u0101jusi nacion\u0101lo val\u016btu devalv\u0101ciju, k\u0101 ar\u012b vairumtirdzniec\u012bbas noliktavu atlikumu optimiz\u0101cija. Min\u0113to faktoru d\u0113\u013c prognoze, ka darb\u012bbas r\u0101d\u012bt\u0101ji Krievij\u0101 \u0161\u012b gada otraj\u0101 pusgad\u0101 uzlabosies, nav sasniegusi pl\u0101noto rezult\u0101tu, savuk\u0101rt neto pe\u013c\u0146as r\u0101d\u012bt\u0101ja samazin\u0101jums ir skaidrojams ar ieguld\u012bjumu pieaugumu p\u0113tniec\u012bb\u0101 un att\u012bst\u012bb\u0101 divos strat\u0113\u0123iskajos projektos. Sadarb\u012bb\u0101 ar Latvijas zin\u0101tniekiem sekm\u012bgi pabeigti kardioprotekt\u012bv\u0101s vielas \u2013 GBB hidroksil\u0101zes inhibitora ar ori\u0123in\u0101lu strukt\u016bru \u2013 \u0137\u012bmiskie un prekl\u012bniskie farmakolo\u0123isk\u0101s efektivit\u0101tes p\u0113t\u012bjumi, kas ir noz\u012bm\u012bgs posms jauna medic\u012bnas prepar\u0101ta rad\u012b\u0161an\u0101. Otrs projekts ir medikamenta Mildron\u0101ts<small>\u00ae<\/small>&nbsp;re\u0123istr\u0101cija \u0136\u012bn\u0101, kur \u0161obr\u012bd tiek veikts prepar\u0101ta 3. f\u0101zes kl\u012bniskais p\u0113t\u012bjums.<\/li><\/ol>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2014. gada devi\u0146os m\u0113ne\u0161os bija 55,6 milj. euro un ir samazin\u0101jies, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada devi\u0146iem m\u0113ne\u0161iem, par 15,7 milj. euro vai 22%. Galvenie gatavo z\u0101\u013cu tirgi ir Krievija, p\u0101r\u0113j\u0101s NVS valstis, Gruzija un Baltijas valstis. Krievijas, p\u0101r\u0113jo NVS valstu un Gruzijas p\u0101rdo\u0161anas apjoms 2014. gada devi\u0146os m\u0113ne\u0161os sasniedza 45,2 milj. euro, kas ir par 16 milj. euro vai 26,2% maz\u0101k nek\u0101 2013. gada devi\u0146os m\u0113ne\u0161os. Augst\u0101ko pieaugumu, sal\u012bdzinot ar 2013. gada devi\u0146iem m\u0113ne\u0161iem, uzr\u0101da Baltkrievija +51%, Azerbaid\u017e\u0101na +36%, Arm\u0113nija +31% un Turkmenist\u0101na +29%. Savuk\u0101rt gatavo z\u0101\u013cu formu p\u0101rdo\u0161anas apjoms Baltijas un cit\u0101s Eiropas valst\u012bs sasniedza 10,4 milj. euro, kas ir par 0,3 milj. euro vai 3,4% vair\u0101k nek\u0101 2013. gada devi\u0146os m\u0113ne\u0161os. 2014. gada devi\u0146os m\u0113ne\u0161os \u201eGrindeks\u201d ir uzs\u0101cis gatavo z\u0101\u013cu eksportu uz vair\u0101kiem jauniem tirgiem \u2013 Lielbrit\u0101niju, Somiju, Slov\u0101kiju, Sp\u0101niju, N\u012bderlandi un Portug\u0101li. Sekm\u012bgi turpin\u0101s pag\u0101ju\u0161\u0101 gad\u0101 uzs\u0101kt\u0101 sadarb\u012bba ar Tunisiju, veidojot +78% pieaugumu, sal\u012bdzinot ar pag\u0101ju\u0161\u0101 gada devi\u0146iem m\u0113ne\u0161iem, un Vjetnamu, palielinot p\u0101rdo\u0161anas apjomu 12,1 reizes. Tirgos, kas atrodas \u0101rpus NVS un Baltijas valst\u012bm, apgroz\u012bjums 2014. gada devi\u0146os m\u0113ne\u0161os, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada devi\u0146iem m\u0113ne\u0161iem, ir palielin\u0101jies par 76%. Visaugst\u0101kais pieaugums, sal\u012bdzinot ar 2013. gada devi\u0146iem m\u0113ne\u0161iem, ir \u010cehij\u0101 +32%.<\/p>\n\n\n\n<p>2014. gada pirmajos devi\u0146os m\u0113ne\u0161os akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 7,4 milj. euro, kas ir par 1,7 milj. euro vai 18,7% maz\u0101k nek\u0101 2013. gada devi\u0146os m\u0113ne\u0161os. Galvenie Grindeks akt\u012bvo farmaceitisko vielu eksporta tirgi 2014. gada devi\u0146os m\u0113ne\u0161os ir N\u012bderlande, V\u0101cija, Kan\u0101da, ASV, Francija, \u012arija un Jap\u0101na. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas ir zopiklons, oksitoc\u012bns, ftoraf\u016brs, droperidols, ksilaz\u012bns, medetomid\u012bns, detomid\u012bns un UDHS.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eDarb\u012bba augsta riska tirgos rada papildu izaicin\u0101jumus, ta\u010du Grindeks turpina izstr\u0101d\u0101t produktus, realiz\u0113t savas ieceres un apg\u016bt jaunus tirgus. Farm\u0101cijas nozarei piem\u012bt specifika \u2013 rezult\u0101tus nav iesp\u0113jams sasniegt \u0101tr\u0101k k\u0101 grib\u0113tos un j\u0101raug\u0101s ilgtermi\u0146\u0101. T\u0101 k\u0101 Grindeks ir uz ilgtermi\u0146a izaugsmi v\u0113rsts uz\u0146\u0113mums, m\u0113s soli pa solim str\u0101d\u0101jam pie da\u017e\u0101du risku mazin\u0101\u0161anas un diversifik\u0101cijas, biznesa att\u012bst\u012bbas jaunos tirgos, un, lai samazin\u0101tu savas darb\u012bbas atkar\u012bbu no situ\u0101cijas k\u0101d\u0101 noteikt\u0101 re\u0123ion\u0101, m\u0113s sl\u0113dzam ar\u012b l\u012bgumus ar jauniem klientiem eso\u0161ajos tirgos. Noz\u012bm\u012bgi faktori, kas liecina par pozit\u012bvu tendenci un uzlabos Grindeks darb\u012bbas r\u0101d\u012bt\u0101jus n\u0101kotn\u0113, ir stabilais piepras\u012bjums p\u0113c Grindeks produktiem un jaunu produktu re\u0123istr\u0101cija da\u017e\u0101dos tirgos.\u201d<\/p>\n\n\n\n<p><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_finansu_parskats_2014_Q3_EUR.pdf\" target=\"_blank\" rel=\"noopener\"><\/a><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_finansu_parskats_2014_Q3_EUR.pdf\" target=\"_blank\" rel=\"noopener\">Grindeks finan\u0161u p\u0101rskats 2014.gada devi\u0146os m\u0113ne\u0161os (371 KB)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piektdien, 28. novembr\u012b akciju sabiedr\u012bbas Grindeks \u201eNASDAQ OMX Riga\u201d iesniegtie 2014. gada devi\u0146u m\u0113ne\u0161u nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums 2014. gada devi\u0146os&#8230;<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1309","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1309"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1309\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}